Page last updated: 2024-11-05

tetrachlorophthalic anhydride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetrachlorophthalic anhydride: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tetrachlorophthalic anhydride : A cyclic dicarboxylic anhydride that is phthalic anhydride chlorinated at the 4-, 5-, 6- and 7-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8326
CHEMBL ID1567912
CHEBI ID59097
SCHEMBL ID21861
MeSH IDM0054065

Synonyms (66)

Synonym
etrachlorophthalic acid anhydride
CHEBI:59097 ,
phthalic anhydride, tetrachloro-
tetrachlorophthalic anhydride
nsc-1484
niagathal
117-08-8
1,5,6,7-tetrachloroisobenzofuran
nsc1484
1, 4,5,6,7-tetrachloro-
4,5,6,7-tetrachloro-2-benzofuran-1,3-dione
inchi=1/c8cl4o3/c9-3-1-2(8(14)15-7(1)13)4(10)6(12)5(3)1
1,3-isobenzofurandione, 4,5,6,7-tetrachloro-
NCGC00091300-01
1,3-dioxy-4,5,6,7-tetrachloroisobenzofuran
ai3-09048
brn 0211560
4,5,6,7-tetrachloro-1,3-isobenzofurandione
einecs 204-171-4
ccris 6202
nsc 1484
nci-c61585
hsdb 2922
cp 626
tetrathal
tetrachlorophthalic anhydride, 96%
NCGC00091300-02
STK256922
AC-11123
FT-0657077
T0071
AKOS003239988
4,5,6,7-tetrakis(chloranyl)-2-benzofuran-1,3-dione
A803707
4,5,6,7-tetrachloroisobenzofuran-1,3-dione
NCGC00091300-03
BBL000527
unii-76glw0lbek
76glw0lbek ,
5-17-11-00260 (beilstein handbook reference)
ec 204-171-4
dtxcid606102
dtxsid7026102 ,
NCGC00256940-01
tox21_303212
cas-117-08-8
tox21_201740
NCGC00259289-01
EPITOPE ID:122674
tetrachlorophthalic anhydride [hsdb]
tetrachlorophthalic acid anhydride
tetrachloro-phthalic acid anhydride
tetrachloro phthalic anhydride
3,4,5,6-tetrachlorophthalic anhydride
SCHEMBL21861
CHEMBL1567912
4,5,6,7-tetrachloro-2-benzofuran-1,3-dione #
1,3-isobenzofurandione, tetrachloro-
1,3-dioxo-4,5,6,7-tetrachloroisobenzofuran
4,5,6,7-tetrachloro-isobenzofuran-1,3-dione
tetrachloro-1,3-dihydro-2-benzofuran-1,3-dione
J-514038
mfcd00005920
VS-00637
Q21045245
EN300-211008

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The rats were orally dosed for 7 d with TCPA suspended in corn oil at 25, 100, 250, or 500 mg/kg."( Effect of tetrachlorophthalic anhydride on hepatic microsomal metabolism in rats and mice.
Nair, RS; Ridley, WP; Warren, J, 1988
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
cross-linking reagentA reagent with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between macromolecules, principally side chains of amino acids in proteins, allowing the locations of naturally reactive areas within the proteins to be identified.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclic dicarboxylic anhydrideAn acid anhydride derived by loss of water between two carboxylic groups in the same molecule so as to close a ring.
tetrachlorobenzeneAny member of the class of chlorobenzenes carrying four chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency54.48270.001530.607315,848.9004AID1224848; AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency61.75280.005428.02631,258.9301AID1346982
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00160.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency48.55770.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (53.85)18.7374
1990's6 (46.15)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.92 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index35.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies2 (15.38%)4.05%
Observational0 (0.00%)0.25%
Other10 (76.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]